2011
DOI: 10.1016/s1470-2045(11)70163-2
|View full text |Cite
|
Sign up to set email alerts
|

Association between KRAS rs61764370 and triple-negative breast cancer—a false positive? – Authors' reply

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2016
2016
2016
2016

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 1 publication
0
1
0
Order By: Relevance
“…However, in a subsequent study, the variant was reported to be associated with increased risk of ER/PR negative disease (80 cases, 470 controls), as well as with triple negative breast cancer diagnosed before age 52 (111 cases, 250 controls), regardless of BRCA1 mutation status [6]. The validity of these findings has been questioned given the very small sample sizes and the number of subgroups tested [16,17]. Another report found no association with sporadic or familial breast cancer risk (695 combined cases, 270 controls), but found that the variant was associated with ERBB2-positive and high grade disease, based on 153 cases who used post-menopausal hormone replacement therapy [18].…”
Section: Introductionmentioning
confidence: 99%
“…However, in a subsequent study, the variant was reported to be associated with increased risk of ER/PR negative disease (80 cases, 470 controls), as well as with triple negative breast cancer diagnosed before age 52 (111 cases, 250 controls), regardless of BRCA1 mutation status [6]. The validity of these findings has been questioned given the very small sample sizes and the number of subgroups tested [16,17]. Another report found no association with sporadic or familial breast cancer risk (695 combined cases, 270 controls), but found that the variant was associated with ERBB2-positive and high grade disease, based on 153 cases who used post-menopausal hormone replacement therapy [18].…”
Section: Introductionmentioning
confidence: 99%